How we approach: Severe congenital neutropenia and myelofibrosis due to mutations in VPS45.
Shadur, Bella; Asherie, Nathalie; Newburger, Peter E; Stepensky, Polina.
Pediatr Blood Cancer
; 66(1): e27473, 2019 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-30294941
Therapeutic potential of Janus-activated kinase-2 inhibitors for the management of myelofibrosis.
Fibrogenesis in Primary Myelofibrosis: Diagnostic, Clinical, and Therapeutic Implications.
Advances in myelofibrosis: a clinical case approach.
Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis.
Clinical and laboratory features of myelofibrosis and limitations of current therapies.
Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies.
An unusual long-term outcome of a child with primary myelofibrosis harboring a JAK2 mutation.
Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management.
Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis.
New strategies in myelofibrosis: the evolving paradigm of disease pathogenesis, prognostication and treatment.